Related Experiment Video
Updated: Apr 26, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.2K
Dopaminergic therapy in aphasia
Sumanjit K Gill1, Alexander P Leff2
1Department of Medicine, Watford General Hospital, Watford, UK.
Aphasiology
|August 1, 2014
Summary
Evidence for dopaminergic agents in aphasia therapy is mixed. Further trials are needed to explore the efficacy of these drugs, like levodopa (L-dopa) and bromocriptine, for improving language function.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- The dopaminergic system modulates critical cognitive functions, including attention, memory, and learning.
- This has led to interest in dopaminergic drugs as potential cognitive enhancers for aphasia patients.
Approach:
- This review analyzes 15 studies (1988-2012) investigating dopaminergic agents, specifically levodopa (L-dopa) and bromocriptine, in aphasia therapy.
- The review examines drug efficacy and explores potential cognitive mechanisms underlying language function and aphasia recovery.
Key Points:
- Despite the broad range of dopaminergic drugs, only a few have been trialled in aphasic patients.
- Published studies offer valuable insights for designing future clinical trials.
- Optimal trial designs should incorporate appropriate control groups or blocks.
Conclusions:
- The efficacy of dopaminergic agents for aphasia is currently inconclusive.
- Further research with well-tolerated agents and robust trial designs is necessary.
- Cognitive mechanisms may involve enhanced word-form relearning or improved retrieval.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:28Drug Therapy
443
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
443
01:29Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K